Compare
C21 Investments Inc. vs Mannatech Inc vs Niagen Bioscience, Inc. vs Natural Alternatives International Inc
| Latest fiscal year | C21 Investments Inc. CWLXF | Mannatech Inc MTEX | Niagen Bioscience, Inc. NAGE | Natural Alternatives International Inc NAII |
|---|---|---|---|---|
| Year ended | 2026-03-31 | 2025-12-31 | 2025-12-31 | 2025-06-30 |
| Revenue | $32.61M | $108.04M | $129.42M | $129.86M |
| Revenue growth (YoY) | +8.3% | -8.3% | +29.9% | +14.1% |
| Gross margin | 41.7% | 74.9% | 64.3% | 7.2% |
| Operating margin | 7.0% | -0.4% | 12.6% | -6.7% |
| Net margin | -9.9% | -14.1% | 13.4% | -10.5% |
| Net income | -$3.24M | -$15.21M | $17.38M | -$13.57M |
| EPS (Diluted) | -$0.03 | -$8.00 | $0.20 | -$2.28 |
| Operating cash flow | $1.36M | -$2.96M | $13.50M | $5.93M |
| Free cash flow | $1.12M | -$4.32M | n/a | $2.32M |
| Cash & equivalents | n/a | $6.18M | n/a | $12.32M |
| Total assets | $54.42M | $29.99M | $106.41M | $151.94M |
| Total liabilities | $28.99M | $35.22M | $29.87M | $83.51M |
| Shareholders' equity | $25.43M | -$5.22M | $76.53M | $68.43M |
| Return on year-end equity | -12.8% | n/a | 22.7% | -19.8% |
| Shares outstanding | 117.84M | 1.90M | 79.71M | 6.18M |
Revenue, most recent five fiscal years
| Fiscal year | C21 Investments Inc. | Mannatech Inc | Niagen Bioscience, Inc. | Natural Alternatives International Inc |
|---|---|---|---|---|
| Latest | $32.61M Ended 2026-03-31 | $108.04M Ended 2025-12-31 | $129.42M Ended 2025-12-31 | $129.86M Ended 2025-06-30 |
| 1 year earlier | $30.12M Ended 2025-03-31 | $117.87M Ended 2024-12-31 | $99.60M Ended 2024-12-31 | $113.80M Ended 2024-06-30 |
| 2 years earlier | n/a | $131.96M Ended 2023-12-31 | $83.57M Ended 2023-12-31 | $154.01M Ended 2023-06-30 |
| 3 years earlier | n/a | $137.21M Ended 2022-12-31 | $72.05M Ended 2022-12-31 | $170.97M Ended 2022-06-30 |
| 4 years earlier | n/a | $159.76M Ended 2021-12-31 | $67.45M Ended 2021-12-31 | $178.52M Ended 2021-06-30 |